Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lux Biosciences, Inc.
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented history of non-infectious intermediate-, anterior and intermediate-, posterior- or panuveitis uveitis
Current uveitis therapy must conform to one of the following:
1. Prednisone monotherapy at a dose of ≥ 10 mg/day (or equivalent) for ≥ 2 weeks prior to randomization
2. Have received ≥ 2 injections of corticosteroid (intravitreal or periocular) for control of disease within the past 8 months, but not within 2 weeks of randomization; subjects may also be receiving systemic corticosteroid therapy
3. Receiving monotherapy with azathioprine, mycophenolate mofetil, mycophenolic acid or methotrexate for at least 2 weeks prior to randomization
4. Receiving prednisone in addition to one immunomodulatory agent from among cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid and methotrexate for at least 2 weeks prior to randomization
5. Subjects for whom corticosteroid therapy (systemic or local) is medically inappropriate or who refuse corticosteroid therapy
Grade of 2+ or higher for vitreous haze at time of enrollment
Considered by the investigator to require immunomodulatory therapy.
Not planning to undergo elective ocular surgery during the study
You may not be if
Uveitis of infectious etiology
Clinically suspected or confirmed central nervous system or ocular lymphoma
Primary diagnosis of anterior uveitis
Clareo Health | A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
